Articul8 launches Bivia to bring domain-specific decision intelligence to enterprise AI agents SPR Therapeutics Debuts Occipital Nerve Stimulation Data at ASRA 2022
One of six total abstracts accepted highlighting benefits of the SPRINT® PNS System CLEVELAND, Nov….
Rakovina Therapeutics Inc. Announces Q3 2022 Financial Results and Provides Corporate Update
VANCOUVER, British Columbia, Nov. 17, 2022 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV, the…
RespireRx Pharmaceuticals Inc. Announces Entry into Letter of Intent with Australian Headquartered CRO for Dronabinol Development for Obstructive Sleep Apnea
Glen Rock, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTC Pink Market:RSPI)…
ABVC BioPharma Provides Vitargus® Update – Phase II Vitargus® Study Protocol Received Thai FDA Approval
FREMONT, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:…
Kane Biotech to Release Third Quarter 2022 Financial Results on November 24, 2022 – Conference Call to Follow
WINNIPEG, Manitoba, Nov. 17, 2022 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company”…
Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced Sarcoma
Overall response rate (ORR) of 46% and disease control rate (DCR) of 69% in heavily…
IMUNON Announces Strategic Investment in Transomic Technologies
Investment of $375,000 with Senior Convertible Notes and Warrants; Strengthens Development Capabilities for IMUNON’s PLACCINE…
SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats
BARDA is seeking to support the development of broad-spectrum, oral/IV antifungal drug candidates with novel…
Palisade Bio Releases In-Depth Explanation of Scientific Approach of Lead Product Candidate LB1148 Through Animated Video
Video illustrates the potential of LB1148 to reduce the formation of adhesions in gastrointestinal (GI)…
VYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo
Topline proof-of-concept data in vitiligo patients expected in 1H 2023 BRIDGEWATER, N.J., Nov. 17, 2022…
Ayala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting
REHOVOT, Israel and WILMINGTON, Del., Nov. 17, 2022 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (Nasdaq:…
Science 37 and Linical Announce Partnership to Enable Fully Decentralized and Hybrid Trials
As a certified partner, Linical will leverage Science 37’s Metasite™ to provide global access to patients…
Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A
BOTHELL, Wash., Nov. 17, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) today announced…
Arcutis’ ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States
ZORYVE is now on formulary for one of the top pharmacy benefit managers serving commercially…
Rezo, Founded by Renowned UCSF Scientists, Launches with $78 Million Series A to Advance Pipeline of Precision Therapeutics Based on Groundbreaking Integrated Disease Network Mapping Platform
–Integration of technologies across proteomics, genetics, structural biology, chemistry, and bioinformatics enables advanced insights into…
TOWER ONE WIRELESS ANNOUNCES THIRTEEN TOWERS COMPLETED – ADDITIONAL NON-CANCELLABLE RENT OF $ 1,500,000
TOWER ONE CONSTRUCTION UPDATE FOR THE MONTH OF OCTOBER 2022 VANCOUVER, BC, CANADA , Nov….
Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research
Phase 1 results showed that AV-101 was generally well tolerated with significantly reduced systemic exposure…
Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of its US Phase 1/2 Clinical Trial for Type 1 Diabetes
Company’s recent recruitment strategy change has resulted in an unprecedented level of inquiries regarding potential…
InMed Provides Update on Management Changes
VANCOUVER, British Columbia, Nov. 17, 2022 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the…
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
EDIT-101 demonstrates a favorable safety profile across all dose cohorts Preliminary efficacy signals of consistent…